Argobio en GeneCode werken samen aan de ziekte van Parkinson in de eerste aangekondigde onderzoeksovereenkomst van Argobio
- Een samenwerking om een nieuwe klasse van mimetica van kleine moleculen te ontwikkelen voor de behandeling van de ziekte van Parkinson en andere indicaties.
- Argobio zal de ontwikkeling van dit innovatieve project tot € 3 miljoen financieren en een nieuw gespecialiseerd biotechnologiebedrijf incorporeren.
- Met € 50 miljoen aan kapitaal zijn Argobio en zijn team van ervaren ondernemers-in-residence van plan om zeer innovatieve projecten te financieren en te ontwikkelen, die zich momenteel in een vroeg stadium van ontwikkeling bevinden, voor de oprichting van toonaangevende biotechbedrijven in gebieden met een hoge medische behoefte.
PARIJS & TALLINN, Estland–(BUSINESS WIRE)– Argobio en GeneCode hebben hun samenwerking aangekondigd voor de ontwikkeling van een kleine molecuul Glial cellijn – Derived Neurotrophic Factor (GDNF) mimetica voor de behandeling van de ziekte van Parkinson en andere indicaties.
In het door Argobio ontwikkelde venture-studiomodel worden baanbrekende technologieën omarmd door een team van wetenschappelijke experts met een ondernemers- en industriële ervaring. Tijdens de incubatieperiode zal Argobio de projectontwikkeling tot 3 ME financieren en de start-up incorporeren. Na incubatie zal verdere durfkapitaalfinanciering worden verstrekt door gespecialiseerde durfkapitaalinvesteerders.
Argobio and GeneCode Partner on Parkinson’s Disease in Argobio’s First Announced Research Agreement
- A collaboration to develop a new class of small molecule mimetics for the treatment of Parkinson’s disease and other indications.
- Argobio will fund the development of this innovative project up to €3 million and incorporate a new specialized biotechnology company.
- With €50M in capital, Argobio and its team of experienced entrepreneurs-in-residence intend to fund and develop highly innovative projects, currently in early-stage development, for the creation of leading-edge biotech companies in areas of high medical need.
PARIS & TALLINN, Estonia–(BUSINESS WIRE)– Argobio and GeneCode have announced their collaboration to develop small molecule Glial cell line – Derived Neurotrophic Factor (GDNF) mimetics for the treatment of Parkinson’s Disease and other indications.
In the venture studio model developed by Argobio, breakthrough technologies are embraced by a team of scientific experts with an entrepreneurial and industrial experience. Over the course of incubation, Argobio will fund the project development up to 3 ME and incorporate the start-up. After incubation, further venture funding will be provided by specialized VC investors.
“The launch of our first collaboration is a great achievement for Argobio. Argobio intends to incubate until series A at least five projects in the fields of rare diseases, neurosciences, and oncology over the next three years. With a committed capital of €50 million, and a team of pharma industry experts, Argobio expects to deliver strong projects, well-prepared for Series A funding,” Thierry Laugel Argobio Chairman said.
GeneCode, a discovery-stage biotech company developing small molecule GDNF mimetics, in collaboration with the laboratory of Mart Saarma, Professor and Research Director of the Institute of Biotechnology, HI-LIFE, University of Helsinki, Finland, has identified and patented a series of small molecules activating the GDNF signalling receptor RET tyrosine kinase. Professor Saarma´s team has discovered GDNF receptors, clarified the GDNF-receptor structure and investigated the therapeutic potential of GDNF family members.
Professor Mart Saarma commented, “Argobio’s investment and participation in the development of effective GDNF mimetics is extremely encouraging news. GDNF mimetics can overcome the limitations of the GDNF protein and can open up a completely new page in the treatment of Parkinson’s disease.”
GeneCode CEO Paavo Pilv added, “Our combined expertise will catapult this technology beyond what we would have been able to achieve alone. Considering the pivotal role of GDNF family ligands and RET signalling pathways for other groups of cells, applications of compounds developed by GeneCode are not limited only to Parkinson’s Disease but can be applied to treat other medical conditions.”
“We have ambitious goals for the next two years,” Argobio Entrepreneur in Residence Yves Ribeill, PhD said. “The whole is greater than the sum of the parts with the combined, diverse expertise of GeneCode, Argobio and Professor Saarma. I am confident that we will be able to demonstrate that the unique business model of funded partnerships initiated by Argobio in Europe will give new therapeutics a boost to succeed.”
About Argobio: www.argobiostudio.com
Argobio is a start-up studio based in Paris, France, dedicated to turning cutting-edge innovations into breakthrough biotech companies. Argobio sources innovative early-stage projects on therapeutics from renowned European academic research institutions with a focus on rare diseases, neurological disorders, oncology, and immunology. Argobio selects and incubates these projects with the goal to create biotech companies and develop (or lead) them up to a significant Series A financing. Argobio provides broad expertise in the discovery and development of novel drugs with a team of highly experienced Biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie and Rémi Soula. Thierry Laugel, Managing Partner at Kurma Partners is the President of Argobio.
Follow us on LinkedIn.
About GeneCode: www.GeneCode.com
GeneCode is a private pharmaceutical development company focused on the development of disease-modifying therapeutics to combat neurodegeneration. The GDNF Mimetics platform leverages the disease-modifying properties of GDNF to small molecules with drug-like properties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005337/en/
Contacts
NewCap – Media relations:
Nicolas Merigeau – nmerigeau@newcap.fr – +33 1 44 71 94 98
Arthur Rouillé – arouille@newcap.fr – +33 1 44 71 00 15
Argobio:
Yves Ribeill – yves.ribeill@argobiostudio.com